doi: 10.1126/science.278.5342.1447.
Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia
Affiliations
- PMID:9367954
- DOI: 10.1126/science.278.5342.1447
Item in Clipboard
Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia
E S Rosenberg et al. Science..
Display options
Format
Display options
Format
Abstract
Virus-specific CD4+ T helper lymphocytes are critical to the maintenance of effective immunity in a number of chronic viral infections, but are characteristically undetectable in chronic human immunodeficiency virus-type 1 (HIV-1) infection. In individuals who control viremia in the absence of antiviral therapy, polyclonal, persistent, and vigorous HIV-1-specific CD4+ T cell proliferative responses were present, resulting in the elaboration of interferon-gamma and antiviral beta chemokines. In persons with chronic infection, HIV-1-specific proliferative responses to p24 were inversely related to viral load. Strong HIV-1-specific proliferative responses were also detected following treatment of acutely infected persons with potent antiviral therapy. The HIV-1-specific helper cells are likely to be important in immunotherapeutic interventions and vaccine development.
Comment in
- How does HIV overcome the body's T cell bodyguards?Balter M.Balter M.Science. 1997 Nov 21;278(5342):1399-400. doi: 10.1126/science.278.5342.1399.Science. 1997.PMID:9411761No abstract available.
- Helper CD4+ T cells and HIV-1.Mor F.Mor F.Science. 1998 Mar 6;279(5356):1436. doi: 10.1126/science.279.5356.1431g.Science. 1998.PMID:9508713No abstract available.
Similar articles
- Reconstitution of virus-specific CD4 proliferative responses in pediatric HIV-1 infection.Feeney ME, Draenert R, Roosevelt KA, Pelton SI, McIntosh K, Burchett SK, Mao C, Walker BD, Goulder PJ.Feeney ME, et al.J Immunol. 2003 Dec 15;171(12):6968-75. doi: 10.4049/jimmunol.171.12.6968.J Immunol. 2003.PMID:14662905
- Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection.Kalams SA, Buchbinder SP, Rosenberg ES, Billingsley JM, Colbert DS, Jones NG, Shea AK, Trocha AK, Walker BD.Kalams SA, et al.J Virol. 1999 Aug;73(8):6715-20. doi: 10.1128/JVI.73.8.6715-6720.1999.J Virol. 1999.PMID:10400769Free PMC article.
- HIV-specific immunity during structured antiviral drug treatment interruption.Moss RB, Brandt C, Giermakowska WK, Savary JR, Theofan G, Zanetti M, Carlo DJ, Wallace MR.Moss RB, et al.Vaccine. 2003 Mar 7;21(11-12):1066-71. doi: 10.1016/s0264-410x(02)00610-2.Vaccine. 2003.PMID:12559781Clinical Trial.
- Cellular immune response to human immunodeficiency virus.Norris PJ, Rosenberg ES.Norris PJ, et al.AIDS. 2001 Feb;15 Suppl 2:S16-21. doi: 10.1097/00002030-200102002-00004.AIDS. 2001.PMID:11424972Review.
- AIDS: decline and fall of immune surveillance?Feinberg MB, McLean AR.Feinberg MB, et al.Curr Biol. 1997 Mar 1;7(3):R136-40. doi: 10.1016/s0960-9822(97)70072-1.Curr Biol. 1997.PMID:9162473Review.
Cited by
- Risk patterns preceding diagnosis among newly HIV-diagnosed men who have sex with men in New York City.Drabkin AS, Sikkema KJ, Wilson PA, Meade CS, Hansen NB, DeLorenzo A, Kochman A, MacFarlane JC, Watt MH, Aunon FM, Ranby KW, Mayer G.Drabkin AS, et al.AIDS Patient Care STDS. 2013 Jun;27(6):333-41. doi: 10.1089/apc.2012.0313.AIDS Patient Care STDS. 2013.PMID:23730703Free PMC article.
- Progressive loss of memory T cell potential and commitment to exhaustion during chronic viral infection.Angelosanto JM, Blackburn SD, Crawford A, Wherry EJ.Angelosanto JM, et al.J Virol. 2012 Aug;86(15):8161-70. doi: 10.1128/JVI.00889-12. Epub 2012 May 23.J Virol. 2012.PMID:22623779Free PMC article.
- Broadening of the T-cell repertoire to HIV-1 Gag p24 by vaccination of HLA-A2/DR transgenic mice with overlapping peptides in the CAF05 adjuvant.Korsholm KS, Karlsson I, Tang ST, Brandt L, Agger EM, Aagaard C, Andersen P, Fomsgaard A.Korsholm KS, et al.PLoS One. 2013 May 17;8(5):e63575. doi: 10.1371/journal.pone.0063575. Print 2013.PLoS One. 2013.PMID:23691069Free PMC article.
- Advancing Human Vaccine Development Using Humanized Mouse Models.Han R, Su L, Cheng L.Han R, et al.Vaccines (Basel). 2024 Sep 4;12(9):1012. doi: 10.3390/vaccines12091012.Vaccines (Basel). 2024.PMID:39340042Free PMC article.Review.
- Advances in understanding immunologic control of HIV infection.Migueles SA, Tilton JC, Connors M.Migueles SA, et al.Curr HIV/AIDS Rep. 2004 Apr;1(1):12-7. doi: 10.1007/s11904-004-0002-2.Curr HIV/AIDS Rep. 2004.PMID:16091218Review.
Publication types
MeSH terms
Substances
Related information
Grants and funding
etc
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials